Acrivon therapeutics reports second quarter 2023 financial results and business highlights

Watertown, mass., aug. 11, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the second quarter ended june 30, 2023 and provided business highlights.
ACRV Ratings Summary
ACRV Quant Ranking